Eton Pharmaceuticals マネジメント
マネジメント 基準チェック /44
Eton Pharmaceuticalsの CEO はSean Brynjelsenで、 Jun2017年に任命され、 の在任期間は 9.25年です。 の年間総報酬は$ 2.91Mで、 24.4%給与と75.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.36%を直接所有しており、その価値は$ 53.35M 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と9年です。
主要情報
Sean Brynjelsen
最高経営責任者
US$2.9m
報酬総額
| CEO給与比率 | 24.44% |
| CEO在任期間 | 9.3yrs |
| CEOの所有権 | 3.4% |
| 経営陣の平均在職期間 | 2.2yrs |
| 取締役会の平均在任期間 | 9yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Sep 09
ETON: Hemangioma Portfolio Momentum Will Drive Future Ultra Rare Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $68 from $60, citing stronger contributions from Hemangeol, upgraded revenue and margin guidance, and added long-term pipeline expectations reflected in a higher future P/E assumption. Analyst Commentary Recent Street research on Eton Pharmaceuticals has focused on strong reported Q2 results, higher revenue and margin guidance, and increasing confidence in the commercial outlook for Hemangeol and other portfolio assets.
ナラティブ更新 • Aug 26
ETON: Pediatric Rare Disease Focus Will Drive Upside From Hemangioma Franchise Expansion
Analysts have raised their fair value estimate for Eton Pharmaceuticals from $62.00 to $76.00, citing higher modeled revenue growth and a higher future P/E multiple supported by recent price target increases following strong Q2 results and Hemangeol performance. Analyst Commentary Recent Street commentary on Eton Pharmaceuticals has been broadly constructive, with multiple bullish analysts lifting their price targets following Q2 results.分析記事 • Aug 19
Forecast: Analysts Think Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Business Prospects Have Improved Drastically
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Aug 14
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Summary Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%. I rate ETON stock a Buy, supported by robust execution, scalable commercial strategy, and a 2-3 year target valuation above $2.5 billion despite current premium multiples. Read the full article on Seeking Alphaナラティブ更新 • Aug 12
ETON: Ultra Rare Focus And New Guidance Will Drive Future Upside
Analysts have raised the fair value estimate for Eton Pharmaceuticals from $40 to $60. This change reflects updated models that factor in higher long term revenue assumptions for key products and recent price target increases across several research firms.ナラティブ更新 • Jul 28
ETON: Ultra Rare Disease Focus Will Drive Long Term Upside Potential
Analysts lifted the fair value estimate for Eton Pharmaceuticals to $62 from $57, reflecting updated price targets in the $60 to $62 range that factor in new product contributions, higher long term revenue assumptions for existing therapies, and more constructive views on its ultra rare disease portfolio. Analyst Commentary Recent Street research on Eton Pharmaceuticals points to a more constructive tone around the stock, with bullish analysts lifting price targets into the US$60 to US$62 range.ナラティブ更新 • Jul 13
ETON: New Guidance And Drug Agreement Will Shape A Balanced Outlook
The analyst price target for Eton Pharmaceuticals has been raised from $52 to $57, with analysts citing updated fiscal 2026 revenue guidance and confidence in the company's growth strategy as key reasons for the change. What’s in the News for Eton Pharmaceuticals Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, sold about 126,685 shares for roughly US$4.77 million between July 2 and July 7, 2026, at weighted average prices near US$37 to US$38 per share, while retaining around 2.7 million shares (source: recent SEC filings summarized in news reports).
ナラティブ更新 • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.ナラティブ更新 • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.ナラティブ更新 • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.ナラティブ更新 • May 03
ETON: Single New Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Analysts have lifted their price targets on Eton Pharmaceuticals by up to $15, citing updated assumptions for revenue growth, profit margins, and future P/E that reflect the recent Hemangeol acquisition and its potential contribution to the business. Analyst Commentary Recent research updates around Eton Pharmaceuticals focus heavily on the Hemangeol acquisition and how it might reshape the company’s growth mix, earnings profile, and valuation assumptions.ナラティブ更新 • Apr 18
ETON: Hemangioma Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Narrative Update on Eton Pharmaceuticals Analysts have raised their price targets on Eton Pharmaceuticals by up to $15, citing the Hemangeol acquisition, its existing FDA approval for infantile hemangioma, and the view that the deal could be accretive with commercialization planned to begin in May. Analyst Commentary Bullish analysts are generally positive on Eton Pharmaceuticals following the acquisition of the U.S. rights to Hemangeol, and several have raised their price targets in response.ナラティブ更新 • Apr 04
ETON: Hemangioma Franchise Expansion Will Reshape Earnings Profile Through 2026
Analysts have raised the consolidated price target for Eton Pharmaceuticals from $30.00 to about $39.33, citing recent target increases from multiple firms and updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Eton Pharmaceuticals focuses heavily on the updated price targets, the Hemangeol acquisition, and how realistic current modeling assumptions appear against execution risks.ナラティブ更新 • Mar 21
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Analysts have raised the Eton Pharmaceuticals price target from $26 to $31, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that reflect their latest views on the company following recent research updates. Analyst Commentary Recent research updates highlight a mix of optimism about Eton Pharmaceuticals' growth opportunities and caution around how quickly those opportunities might translate into earnings and justify higher valuation multiples.分析記事 • Nov 14
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Share Price Matching Investor Opinion
With a price-to-sales (or "P/S") ratio of 6.4x Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) may be sending very bearish...分析記事 • Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 25% after a relatively good period...新しいナラティブ • May 16
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.分析記事 • May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a pretty great week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, with its shares surging 14...分析記事 • May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders are no doubt pleased to see that the share price has bounced...分析記事 • Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...分析記事 • Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...分析記事 • Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
The Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) share price has done very well over the last month, posting an excellent...分析記事 • Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a really impressive month, gaining 40% after a shaky period...分析記事 • Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Market forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering...分析記事 • Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) earnings announcement last week was disappointing for investors, despite...分析記事 • Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 26% after a relatively good period...分析記事 • Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$13m |
| Mar 31 2026 | n/a | n/a | -US$1m |
| Dec 31 2025 | US$3m | US$712k | -US$5m |
| Sep 30 2025 | n/a | n/a | -US$7m |
| Jun 30 2025 | n/a | n/a | -US$4m |
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$2m | US$616k | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | US$913k |
| Dec 31 2023 | US$2m | US$592k | -US$936k |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$234k |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$2m | US$570k | -US$9m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$2m | US$542k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$476k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$2m | US$410k | -US$18m |
報酬と市場: Seanの 総報酬 ($USD 2.91M ) は、 US市場 ($USD 5.29M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Seanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Sean Brynjelsen (54 yo)
9.3yrs
在職期間
US$2,914,489
報酬
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 9.3yrs | US$2.91m | 3.36% $ 53.3m | |
| Chief Business Officer | 3.5yrs | US$1.39m | 0.13% $ 2.1m | |
| Consultant | less than a year | US$1.40m | 0.056% $ 885.7k | |
| Chief Commercial Officer | 1.8yrs | US$575.29k | 0.0010% $ 16.0k | |
| Chief Financial Officer & Secretary | less than a year | データなし | データなし | |
| Chief Operating Officer | 2.7yrs | データなし | 0.079% $ 1.2m | |
| Senior Vice President of Sales Operations | no data | データなし | データなし |
2.2yrs
平均在職期間
49yo
平均年齢
経験豊富な経営陣: ETONの経営陣は 経験豊富 であると考えられます ( 2.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 9.3yrs | US$2.91m | 3.36% $ 53.3m | |
| Independent Director | 9yrs | US$277.84k | 0.25% $ 4.0m | |
| Independent Director | 9.3yrs | US$275.14k | 0.24% $ 3.8m | |
| Independent Chairman | 9yrs | US$318.05k | 0.78% $ 12.4m | |
| Independent Director | 5.5yrs | US$267.03k | 0% $ 0 |
9.0yrs
平均在職期間
68yo
平均年齢
経験豊富なボード: ETONの 取締役会 は 経験豊富 であると考えられます ( 9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 15:53 |
| 終値 | 2026/09/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Eton Pharmaceuticals, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Gary Nachman | Canaccord Genuity |